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Monitoring multiple angiogenesis-related molecules in the blood of cancer patients 
shows a correlation between VEGF-A and MMP-9 levels before treatment and 
divergent changes after surgical vs. conservative therapy 
Khalil Zaman1'2, Robert Drisco111'2, Diane Hahn3, Patricia Werffeli1•2, Simon L. Goodman3, Jean Bauer1, 
Serge Leyvraz1, Ferdy Lejeune1, Roger Stupp1 and Curzio Rüegg1•2* 
1Centre Pluridisciplianire d'Oncologie (CePO), Faculty of Biology and Medicine, University of Lausanne, Lausanne, Switzerland 
2Swiss lnstitute for Experimental Cancer Research (ISREC), NCCR Molecular Oncology, Epalinges s/Lausanne, Switzerland 
3Merck, KGaA, Oncology Research, Darmstadt, Germany 
Anti-angiogenic therapies are currently in cancer clinicat trials, 
but to date there are no established tests for evaluating the angio-
genic status of a patient. We measured 11 circulating angiogene-
sis-associated molecules in cancer patients before and after local 
treatment. The purpose of our study was to screen for possible 
relationships among the different molecules and between individ-
ual molecules and tumor burden. We measured VEGF-A, PIGF, 
SCF, MMP-9, EDB+·fibronectin, sVEGFR-2, sVEGFR-1, set:Vp3, 
sTie-2, IL-8 and CRP in the blood of 22 healthy volunteers, 17 
early breast, 17 early colorectal, and 8 advanced sarcoma/mela-
noma cancer patients. Breast cancer patients had elevated levels 
of VEGF-A and sTie-2, colorectal cancer patients of VEGF-A, 
MMP-9, sTie-2, IL-8 and CRP, and melanoma/sarcoma patients 
of sVEGFR-1. set:VP3 was decreased in colorectal cancer patients. 
A correlation between VEGF -A and MMP-9 was found. After 
tumor removal, MMP-9 and set:VP3 significantly decreased in 
breast and CRP in colorectal cancer, whereas sVEGFR-1 
increased in colorectal cancer patients. In sarcoma/melanoma 
patients treated regionally with TNF and chemotherapy we 
observed arise in VEGF-A, SCF, VEGFR-2, MMP-9, Tie-2 and 
CRP, a correlation between CRP and IL-8, and a decreased in 
sVEGFR-1 levels. In conclusion, among ail factors measured, only 
VEGF-A and MMP-9 consistently correlated to each other, ele-
vated CRP Ievels were associated with tumor burden, whereas 
sVEGF-Rl increased after tumor removal in colorectal cancer. 
Treatment with chemotherapy and TNF induced changes consis-
tent with an angiogenic switch. These results warrant a prospec-
tive study to compare the effect of surgical tumor removal vs. che-
motherapy on some of these markers and to evaluate their prog-
nostic/predictive value. 
© 2005 Wiley-Liss, !ne. 
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chemotherapy 
Angiogenesis promotes local tumor progression and invasion 
and enables tumor cell dissemination and metastasis formation. 1 
Many preclinical studies show that the inhibition of angiogenesis 
can suppress tumor growth and metastatic dissemination. Bevaci-
zumab (Avastin®), a neutralizing antibody specific for vascular 
endothelial growth factor (VEGF)-A in combination with standard 
chemotherapy (i.e., CPT-11, 5-FU and Leucovorin) extends sur-
vival, and this combination was approved for patients with 
advanced colorectal cancer.2 This result represents a proof-of-con-
cept for the raie of angiogenesis in human cancer progression and 
demonstrates that VEGF-A is a valid molecular target for the man-
agement of colon cancer. 
The inhibition of the formation of new vessels, or the disruption 
of established vessels is not easily seen using the standard 
response criteria of clinical oncology because these are based 
mainly on measurement of tumor size. The ability to monitor 
tumor angiogenesis in patients would greatly facilitate the clinical 
development of anti-angiogenic treatments. Sorne imaging techni-
ques, such as angiography, contrast-enhanced dynamic nuclear 
magnetic resonance, computer tomography and position emission 
tomography allow perfusion measurements at tumor sites, but they 
are not routinely used in the clinic as they are expensive and 
require sophisticated equipment and expertise. No validated bio-
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chemical marker cun-ently allows the reliable monitoring of tumor 
angiogenesis in patients.3•4 
Severa! molecules implicated in angiogenesis have been identi-
fied, some detectable in the srtemic circulation. VEGF-A, matrix 
metalloproteinase (MMP) -2 and MMP-9,6 soluble VEGF recep-
tor-1 (sVEGFR-1),7 soluble VEGF receptor-2 (sVEGFR-2)8 and 
soluble Tie-2 (sTie-2) 7 have been studied in a wide variety of can-
cers, including breast, ovary, brain, kidney, bladder, prostate, lung, 
gastro-intestinal cancers, hematolo~ical malignancies, hepatocar-
cinoma, melanoma and sarcomas. 3• - 11 Correlations between ele-
vated levels of some of these molecules, in particular VEGF-A 
and MMP, and the presence of a tumor, its sta?e or grade, progres-
sion and clinical outcome have been reported. 2•13 In most studies, 
only one or a few markers were evaluated simultaneously. The 
possibility of improving sensitivity or specificity by the simultane-
ous measurement and analysis of multiple candidate markers has 
not yet been evaluated. 
We measured in parallel 11 different angiogenesis-associated 
molecules in the blood of patients before and after curative-intent 
loco-regional treatment and of healthy volunteers. We selected 
these markers from previous reports of their altered levels in tissue 
or blood of cancer patients or because preclinical and pathological 
studies have indicated an association with tumor angiogenesis. 
Placenta growth factor (PIGF) and VEGF-A are vascular growth 
factors that bind to and activate VEGFR-1 and VEGFR-1/-2, 
respectively. PIGF has been reported recently to play a role in 
pathological angiogenesis, 14 but its biological and clinical rele-
vance in cancer are unclear. Stem Cell factor (SCF) promotes 
release of hematopoietic and vascular progenitor cells from the 
bone marrow. 15 VEGFR-1 and VEGFR-2 are receptors for the 
VEGF family members, which can induce angiogenesis. 16 Integrin 
ex Vf33 is a cell adhesion receptor highly upregulated on angiogenic 
endothelial cells.17 Tie-2 is a receptor for the angiopoietins, which 
promotes endothelial cell survival and vascular remodeling. 18 
MMP-9 is a matrix-degrading enzyme upregulated in inflamma-
tion and cancer that was found to induce the angiogenic switch in 
preclinical cancer models. 19 EDB + -fibronectin (EDB + -Fn) is a 
fibronectin-splice variant absent from most normal tissues, but 
Abbreviations: BC, breast cancer; CRC, colorectal cancer; CRP, C-
reactive protein; EDB-Fn, extra-domain B positive fibronectin; HV, 
healthy volunteers; IL-8, interleukin-8; ILP, isolation Iimb perfusion; 
MMP-9, matrix metalloproteinase-9; PLGF, placenta growth factor; SCF, 
stem cell factor; sVEGF-Rl, soluble VEGF-receptorl; sVEGF-R2, soluble 
VEGF-receptor2; TNF, tumor necrosis factor; VEGF-A, vascular endothe-
lial growth factor A. 
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expressed in tumors in close association with angiogenic vessels,20 
although the EDB domain itself is dispensable for tumor angio-
genesis and tumor progression.21 Interleukin (IL)-8 has been asso-
ciated with tumor progression and angiogenesis in several cancers, 
including breast, prostate and colorectal. 22•23 It was reported 
recently that Ras-dependent IL-8 secretion is critically involved in 
initiating tumor-associated inflammation and neovasculariza-
tion.24 Elevated serum C-reactive protein (CRP) levels were 
reported to be associated with elevated risk of developing colorec-
tal cancer,25 a more aggressive progression and unfavorable prog-
nosis.26 More recently elevated CRP levels were found associated 
with angiogenic factors in multiple myeloma.27·28 
The aim of our study was to identify possible trends and 
relationships between these factors, which could subsequently be 
validated in prospective trials for their prognostic or predictive 
value. Our study was carried out on patients with localized and 
previously untreated breast or colorectal cancers scheduled to 
undergo primary curative-intent resection. We also analyzed 
patients undergoing local treatment by isolated limb perfusion 
with high dose TNF and chemotherapy for locally advanced/ 
relapsed melanoma or sarcoma.29 This modality of treatment per-
mitted us to explore the difference of angiogenic response 
between loco-regional surgery compared to chemotherapy. 
Material and methods 
Study population 
Eligible patients were 18 years of age or older, presenting non-
metastatic breast (BC) or colorectal cancer (CRC) and scheduled 
for tumor resection, and loco-regional refractory or relapsed mela-
noma or sarcoma scheduled for isolated limb perfusion (ILP). 
Exclusion criteria included patients with < 10 g/dl hemoglobin, 
leucopenia, thrombocytopenia, deep verrous thrombosis during the 
last 3 months, long-term vascular catheter, chronic vascular or 
inflammatory disease, surgery and chemotherapy during the last 
4 and 6 months respectively. 
ILP is a technique of locoregional treatment30 where tumor 
necrosis factor alpha (TNFa, Beromun®; dose = 1-4 mg) and 
high dose melphalan (Alkeran®; 10 mg/l of the limb volume) are 
perfused through an extracorporeal circulation into a limb isolated 
from the systemic circulation by a tourniquet. For melanoma, 
gamma interferon (IFN-y, Imukin®; 0.2 mg) is also added in the 
perfusion. 
Healthy volunteers were at least 18 years old, without history of 
cancer, chronic disease or medication other than hormonal contra-
ception. Ethical and scientific approval were given by the local 
Ethics Committee. Written informed consent was obtained from 
all the patients and healthy volunteers. 
Study design 
Blood was obtained before and more than 4 weeks after treat-
ment by peripheral verrous puncture. Serum and plasma were 
extracted during the following 2 hr. 
Plasma isolation 
Blood was collected in heparin containing tubes. After 30 min 
centrifugation at 400g at 20°C, the plasma was extracted and fro-
zen at -80°C. 
Senan isolation 
Blood was collected in tubes without anticoagulant. After 10 min 
centrifugation at l,OOOg, the serum was extracted and frozen at 
-80°C. 
Samples analyses 
The samples were thawed just before use. Ail molecules were 
measured in serum, except for VEGF-A, MMP-9, savf)3, 
sVEGFR-1, sVEGFR-2, which were measured in heparin-plasma 
to avoid potential interfering effects due to platelets activation 
during clotting. Measurements ofVEGF-A, PIGF, SCF, sVEGFR-
1, sVEGFR-2, SCF, MMP-9 and sTie-2 were carried out using the 
Quantikine ELISA systems (R&D Systems, Abingdon, UK). The 
sVEGFR-1 Quantikine ELISA does not differentiate between 
sVEGFR-1 generated by alternative splicing and sVEGFR-1 gen-
erated by proteolytic cleavage at the cell surface. IL-8 was meas-
ured using and ELISA system from Amersham Bioscience (Buck-
inghamshire, UK). CRP was measured using an ELISA system 
from Hyphen BioMed (Neuville-sur-Oise, France). EDB+ -Fn was 
measured with an ELISA by Adeza Biomedical (Sunnyvale, CA). 
sa Vf)3 was measured using an ELISA developed for our study 
(see below). Each data point was measured in duplicate. Optical 
density of each well was measured at 450 nm in a multiwell plate 
reader (Packard Spectra Count, Meriden, CT). For practical rea-
sons, only means are described below, as there was very little 
divergence between means and medians. To identify putative cor-
relations between the levels of individual factors they were com-
pared to each other. 
Capture ELISA for soluble avf33 
Anti-integrin aV (clone 272-17E6, Calbiochem, San Diego, 
CA) was adsorbed on 96-well plates (MaxiSorp, Nunc, Roskilde, 
Denmark) from a coating solution of 2 µg/ml in PBS (1 hr at 4°C). 
Plates were blocked with 5% BSA in PBS. The assay was carried 
out in PBS containing 0.1 % BSA and 0.01 % Tween 20 (dilution 
buffer). Plasma samples were diluted and incubated on the plates 
for 60 min at 37°C. After washing, biotinylated anti-[)3 antibody 
at 2 µg/ml (clone 20H9)31 was incubated on the plates for 60 min 
at 37°C. Plates were washed with dilution buffer, and anti-biotin 
peroxidase conjugate (Sigma, Deisenhofen, Germany) was added 
for 60 min at 37°C. Results were quantified by comparison to a 
reference curve produced using purified recombinant savf)3.32 
Statistical analysis 
Analysis was descriptive and exploratory. Mann-Whitney 11-test 
was used in the comparison between healthy volunteers and can-
cer patients. The changes in the levels of factors before and after 
treatment were estimated by Wilcoxon signed-rank test. Results 
were considered statistically significant for p ::::; 0.05. 
Results 
Study population 
Forty-six patients were recruited, 4 patients were excluded from 
the analysis because of the absence of an invasive cancer (3 BC 
patients) or the presence of metastatic disease (1 CRC patient). Of 
the 42 eligible patients there were 17 female BC patients, 17 CRC 
patients and 8 cases of loco-regional relapsing/refractory sarcoma 
or melanoma (ILP patients). Patient characteristics are described 
in Table I. 
Breast cancer (BC). Thirteen patients with invasive cancer 
were treated by tumorectomy and 4 patients by mastectomy. Axil-
lary lymph node and sentine! node dissection were carried out in 
11 and 6 patients, respectively. Post-surgery blood samples were 
obtained at a median time of 6.9 weeks after treatment. 
Colorectal cancer (CRC). Tumor localizations were in rectum 
(11 = 2), rectosigmoid (11 = 3) and colon (11 = 12). Patients were 
treated by hemicolectomy (11 = 14) and low anterior resection 
(11 = 3). Pcst-surgery blood samples were obtained at a median 
time of 8.9 weeks after treatment. 
/solated limb pe1fusio11 (ILP) patients. Four sarcoma patients 
were included (1 liposarcoma Grade 2, 1 angiosarcoma Grade 3 
and 2 synovial sarcomas, Grade 2 and 3). The indications for ILP 
in sarcoma patients were progression after first line surgery, bulky 
initial tumors and first local relapse. No lymph node or distant 
metastases were present before ILP. Melanoma patients were 
treated by ILP for in transit metastasis. Post-surgery blood sam-
ANGIOGENESIS MARKERS IN PERIPHERAL BLOOD 
TABLE 1 - STUDY POPULATION CHARACTERISTICS 
Breast cancer 
Histology 
Tumor size 
Lymph node invasion 
Stages 
Positive hormonal 
receptor 
Grade 
Colorectal cancer 
Gender 
Tumor size 
Lymph node metastasis 
Stage 
Grade 
ILP 
Histology 
No. ofpatients1 
Ductal invasive carcinoma = 15 
Lobular invasive carcinoma = 1 
Medullar invasive carcinoma = 1 
Tl= 10; T2 = 7 
7 
Stl = 7; St2 = 7; St3 = 2; 
local relapse = 1 
14 
G1 = 2; G2 = 9; G3 = 6 
Female = 5; Male = 12 
Tl = 1; T2 = 4; T3 = 7; T4 = 5 
8 
Stl = 3; St2 = 6; St3 = 8 
G1 = 2; G2 = 13; G3 = I; ND= 1 
Melanoma4 
Sarcoma 4 
1 Forty-two cancer patients were analyzed in this study: 17 female 
breast cancer patients, 17 colorectal cancer patients and 8 cases of 
loco-regional relapsing/refractory sarcoma or melanoma, ND, not 
done. 
pies for ILP patients were obtained at a median time of 7.4 weeks 
after treatment. 
Measured concentrations of the individualfactors 
VEGF-A. The differences of the mean values between volun-
teers and cancer patients (Table II, Fig. la) were statistically sig-
nificant for BC (p = 0.036) and CRC (p = 0.001). After surgical 
tumor resection a trend toward a decrease of the mean levels of 
VEGF-A was observed for BC and CRC. In 6 CRC patients, how-
ever, VEGF-A levels slightly increased after surgery (Table III, 
Fig. lb). In ILP patients, an increase in VEGF-A concentration 
after therapy was observed in ail patients, except one who had ele-
vated level of VEGF-A at baseline (Table III, Fig. le). Of note is 
that this patient had in transit metastases of melanoma and subse-
quently developed a disseminated disease within 1 month. There 
was no correlation between platelets count and VEGF-A in the 
patients, thus excluding that we were measuring VEGF-A released 
from platelets.33 
PIGF and SCF. No significant differences were observed for 
PIGF and SCF between healthy volunteers and BC, CRC or 
patients undergoing ILP (Table II). Treatment had no significant 
effect on PlGF levels. SCF levels did not change after treatment in 
BC and CRC whereas it rose by approximately 20% in ILP 
patients (Table III). 
sVEGFR-1. The mean values of sVEGFR-1 were only slightly 
higher in BC and CRC patients compared to healthy volunteers 
whereas it was significantly higher in ILP patients compared to 
contrais (Table II, Figure 2a). After treatment we observed a ten-
dency of increasing values in BC patients, a significant increase in 
CRC patients and a significant decrease in ILP patients (Table III, 
Figure 2b and 2c). 
sVEGFR-2. Only minor differences in sVEGFR-2 mean values 
were observed between healthy volunteers and cancer patients. 
CRC patients had significantly lower levels of sVEGFR-2 com-
pared to healthy volunteers, but the difference was small (13%) 
(Table Il). No relevant modifications were observed after treat-
ment in BC and CRC patients, whereas the sVEGFR-2 mean level 
rose significantly in ILP patient (Table III). 
sTie-2. The mean values of Tie-2 were significantly higher in 
BC and CRC patients, compared to healthy volunteers, although 
the differences were small (Table II). After treatment no relevant 
changes were observed in BC and CRC patients, whereas in ILP 
patients sTie-2 levels rose significantly (Table III). 
oq"1:0\~8C'f!O\ 
........ ,-(o;i.not.n~ 
tl tl 0 tl c:) tl 0 
7 7 Il t-- Il t-- Il 
.....;.....; .,,>.ë .,,..r.,, 
0 0 0 
"!irit--'<f\OC'i-ooNo;C'h~0\8 
tl tl 0 tl 0 tl c:) 
~ ") Il "1 Il 0) Il (::îg) .,,~ .,,~.,, 
..... 
Nlrl OO 7 
:::~;;b~~~&:; 
tl tl c:) tl c:) tl c:) 
o; "1 11 "1 Il "l Il 
~~.,,)El .,,8.,, 
t--t-- t-- OO 
MN ,..-( 0 
• • t-- • 0\ •OO 
77c<1"1N70 
tl tl c:) tl c:) tl c:) 
\0 0 Il - Il OO Il 
.,........ . . 
OO ~s ~::: ~ 
757 
-- Ci~ ~ (") Ci a.(D~~~a --~Ctl o..g ~ ~ ga1-1a-.<~a 
..... ..... (1l c (il~@ .......... ~(")~ 
a ::i ~ § cJQ·§ ~ 
'"°'9o;:r0,_. §~Ctl~~~I ~ ~ g"Cï5"-<'@< 
-~ -·"" mnm li: (il ;:l ci ci~ Cl 
~~8371§~ 8-,,.,>o..> (1> 0 
~ 1-1 "O .......... (") .......... ~~~~~~ 
-- ..... (1l (il 0 (tl :e.aooaoo 
r-4n;:_n ~;_ 
'1:1§ Poe:..~ 
"O 0 '1:1.g 0 < ê.~":-"~ § tT1 
(1>"0~(1> 0 Cl g~~0..~7.1 
~@:·<on> ;:r~trl;:r:;o< (l>?'Cl<l>()O> 
OO 7j e,..._, 2'" 
g~>~-g f] 
::::;. <~ < §'·g-5 m E"~g~ 
~-~~ g ;@ 
0 1 Ci (tl ~ ..... g>g,~o..@ 
~ 0 en r.r.i ~ 
:: ~ (ti ~a0· s 
ËÏ'"' § ~ 8. g ~~o...._,~r:-
VEGF-A concentration (pg/mQ 
OJ 
(!) 
ë' 
~ (!) 
0 
->. 
0 
0 
!\,) 
0 
0 
(J.) 
0 
0 
~I\\~"" 
A 
0 
0 
()'! 
0 
0 
-r 
-u 
Q) 
0 
0 
(") 
VEGF-A concentration (pg/ml) 
OJ (!) 
ë' 
~ 
CD 
0 
->. I'-.) 
8 8 
~~ 
(J.) 
0 
0 8 g 0 (j) 0 0 
~ 
tT 
VEGF-A concentration (pg/ml) 
I 
< 
0 
...>. 
0 
0 
•• 
~ t-t•. 
~ ~ -·I·. 0 
r= ~- .. 
-u 
!\,) 
0 
0 
• 
• 
(J.) 
0 
0 
A 
0 
0 
()'! 
0 
0 
• 
(]) 
0 
0 
m 
TABLE III-MEAN LEVELS OF THE MEASURED FACTORS BEFORE AND AFTER TREATMENT 
VEGF PIFG SCF sVEGFR-1 sVEGFR-2 sTie-2 saVj33 MMP-9 EDB-Fn IL-8 CRP 
pg/ml ± SD pg/ml ± SD pg/ml ± SD pg/ml ± SD pg/ml ± SD µg/ml ± SD ng/ml ± SD ng/ml ± SD ng/ml ± SD pg/ml ± SD µg/ml ± SD 
BC 
Before 52.9 :': 29.2 10 :': 4.2 744.5 :': 155 29.3 :': 25.0 8824 :': 1088 25.2 :': 4.8 24.3 :': 6.6 237.8 :': 165.8 2.6 :': 1.7 3.3 :': 3.2 1.4 :': 1.4 
p = 0.12 p = 0.93 p = 0.12 p = 0.49 p = 0.25 p = 0.34 p = 0.04 p = 0.02 p = 0.76 p = 0.10 p = 0.22 
After 43.8 :': 24.5 10.2 :': 5.0 729.2 :': 162 64.5 :': 157.6 8672 :': 1542 24.4 :': 4.9 21.7 :': 5.2 109.6 :': 64.8 2.7 :': 1.5 1.8 :': 0.9 1.8 :': 1.7 
CRC 
Be fore 109.6 :': 128.1 10.1 :': 3.1 726.5 :': 158 23.5 :': 24.0 8104 :': 1153 25.5 :': 7.7 12.7 :': 6.6 370.1 :': 338.8 1.9 :': 1.4 7.4 :': 12.0 6.7 :': 5.0 
p = 0.19 p = 0.24 p = 0.43 p = 0.01 p = 0.26 p = 0.51 p = 0.55 p = 0.12 p = 0.12 p = 0.09 p = 0.04 
After 57.6 :': 41.8 10.8 :': 4.7 776 :': 196 310.7 :': 880 8626 :': 1764 24.6 :': 6.3 12.l :': 7.5 190.3 :': 127.8 2.3 :': 1.7 3.3 :': 1.3 3.4 :': 3.9 
ILP 
Be fore 51.8 :': 60.6 11.8 :': 4.0 803.3 :': 164 122.9 :': 92.0 8258 :': 2238 17.9±1.3 18.2 :': 4.3 243.1 ± 342.5 6.3 :': 5.6 4.4 :': 5.6 4.7 ± 5.3 
p = 0.09 p = 0.58 p = 0.01 p = 0.02 p = 0.02 p = 0.01 p = 0.78 p = 0.16 p = 0.21 p = 0.77 p = 0.02 
After 123.4 :': 83.2 10.7 :': 4.7 949.4 :': 160 18.2 :': 11.6 10135 :': 1924 25.1 :': 4.0 17.8 :': 5.7 332.6 :': 242.1 7.3 :': 5.7 3.1 :': 5.8 7.3 :': 7.1 
Breast and colorectal cancer patients were treated by surgery whereas melanoma and sarcoma patients were treated by isolated limb perfusion with TNFœ, IFN'Y and Melphalan. Bold typing 
denotes values that are significantly different in cancer patients after therapy compared to pre-treatrnent values. HV, healthy volunteers; BC, breast cancer; CRC, colorectal cancer; ILP, sarcoma 
or melanoma. Results represent mean values ± SD. p :':'.'. 0.05 was considered statistically significant. 
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FIGURE 2 - sVEGFR-1 levels. (a) sVEGFR-1 values before treat-
ment: sarcoma and melanoma patients had significantly higher levels 
compared to healthy volunteers. (b) sVEGFR-1 values before and after 
therapy in colorectal cancer patients: values were higher after surgical 
tumor removal. (c) sVEGFR-1 values before and after therapy in sar-
coma and melanoma patients before and after ILP: sVEGFR-1 
decreased after therapy. The short horizontal lines indicate mean values. 
saVf33. The mean values of so:Vl33 were significantly lower in 
CRC and ILP patients compared to healthy volunteers, whereas in 
BC patients sa Vl33 concentrations were comparable to healthy 
donors (Table II). A minor, but statistically significant decrease in 
so:Vl33 was observed in BC patients after therapy (Table III). In 
CRC and ILP patients so:Vl33 levels were not affected by the treat-
ment. There was no correlation between the so:Vl33 level and 
number of circulating platelets. 
MMP-9. The mean concentrations of MMP-9 were higher in 
ail patient populations, compared to healthy donors, although the 
difference was statistically significant only in CRC patients (Table 
II, Fig. 3a). After treatment we observed a significant drop in the 
mean levels of MMP-9 in BC patients, a trend toward decrease 
concentrations in CRC patients and a trend toward increased lev-
els in ILP patients (Table III, Fig. 3b,c). 
EDB+ -Fn. The mean values of EDB+-Fn were significantly 
lower in BC, CRC and ILP patients than in healthy volunteers 
(Table II). EDE+ -Fn levels were slightly higher after treatment 
than before therapy, but the modifications did not reach signifi-
cance in any of the cancer types (Table III). 
IL-8. The mean values of IL-8 were significantly higher in 
CRC patients compared to healthy volunteers (Table II). These 
elevated levels decreased upon tumor removal, but did not reach 
statistical significance (Table III). 
CRP. Mean CRP levels were elevated in CRC and ILP 
patients, but reached statistical significance only in CRC patients 
(Table II, Fig. 4a). CRP levels returned within the normal range in 
CRC patient upon surgical tumor removal, whereas they increased 
significantly in ILP patients after treatment (Table III, Fig. 3b,c). 
Correlation between different factors 
The analyses of the results showed that subjects with higher 
pre-treatment levels of VEOF-A tended to have higher levels of 
MMP-9 and the converse. This coITelation was observed in both 
BC and CRC patients, although it was most relevant for the latter 
(R2 = 0.58 and R2 = 0.77, respectively) (Fig. 5a and not shown). 
In ILP patients we also observed a strong correlation, which, how-
ever, was largely influenced by one single patient (R2 = 0.95; if 
highest value omitted, R2 = 0.55) (Fig. 5b). There was a trend for 
a correlation between elevated IL-8 levels and VEOF-A and 
MMP-9 concentrations (R2 = 0.604 and R2 = 0.402, respectively, 
data not shown). Similarly CRP and MMP-9 levels and CRP and 
VEOF-A levels tended to correlate (R2 = 0.43 and R2 = 0.36, 
respectively), although to a lesser extent. There was a correlation 
between post-treatment levels of IL-8 and CRP in ILP patients 
(R2 = 0.69) (Fig. 5c). No other relevant positive or negative corre-
lations were observed between any of the other factors. 
Correlation with clinical parameters 
Given the small number of patients these correlations are only 
indicative of trends based on median values. 
VEGF-A. In BC we observed a trend between increased 
VEOF-A levels and advanced tumor stage (Stage I < Stage II < 
Stage III), size (Tl < T2), grade (O 1 < 02 < 03), absence of 
estrogen receptor expression (negative > positive) and lymph 
node invasion (negative < positive). In colorectal cancer, VEGF-
A levels were higher in patients with larger tumors, higher tumor 
stages (Stage I < Stage II-III), tumor infiltration (Tl < T2 < T3) 
and lymph node invasion (Nl < N2). 
sVEGFR-l. In BC patients lower sVEOFR-1 levels were asso-
ciated with higher stages (Stage 1 > Stage II > Stage Ill), larger 
tumors (Tl > T2) and lymph node infiltration (negative > posi-
tive). In CRC patients, however, the trend was the opposite: 
sVEOFR-1 levels were higher for higher stages (Stage I < Stage 
Il-III), tumor infiltration (Tl < T2-T3) and lymph node invasion 
(Nl < N2). 
MMP-9. In BC, MMP-9 levels were higher in higher stages 
(Stage I < Stage II < Stage III) and higher tumor size (Tl < T2). 
760 ZAMAN ETAL. 
a 
=- 120u 
~ g 1000 
c 
0 800 ;;:::; 
œ 
...... 
c 600 ~ 
c 
0 400 ..&.. (.) 
O> 
"'!"' ...... ' o... 200 :2 -
:2 1 
0 
HV BC CRC ILP 
b 
,..-..... 1200 
:ê 
0) 1000 c 
BC 
c 800 0 :p 
œ 
c: 600 ~ 
c 
0 400 (.) 
O> 
ci 200 
:2 
:2 0 
Be fore After 
c 
.:::::- 1200 
E 
~ 1000 
._, 
c 
0 800 :p 
~ 
c 600 Q) 
(.) 
c 
8 400 
(J) 
ci 200 :2 
:2 0 
Before After 
FIGURE 3 - MMP-9 levels (a) MMP-9 values before treatment. Col-
orectal cancer patients had significantly higher levels compared to 
healthy volunteers. (b) Values before and after treatment in breast can-
cer patients. (c) Values before and after treatment in colorectal cancer 
patients. HV, healthy volunteers; BC, breast cancer; CRC, colorectal 
cancer; ILP, sarcoma and melanoma patients. The short horizontal 
lines indicate mean values. 
In CRC, higher MMP-9 correlated with the stage (Stage I < 
Stages Il-III) tumor infiltration (Tl < T2 < T3) and lymph node 
invasion (Nl < N2). 
Discussion 
Our work was initiated as an exploratory study aimed at meas-
uring multiple angiogenesis-associated molecules in the blood of 
cancer patients, analyzing putative correlations and identifying 
molecules as candidate markers for further investigation in pro-
spective clinical studies. Each factor was measured within the 
same patient before and after resection of the primary tumor (BC 
and CRC). The measurements were also carried out in a small 
group of patients undergoing curative-intent regional chemother-
apy with TNF for loco-regionally advanced sarcoma or melanoma 
of the Iimb, and in healthy individuals. 
In breast and colorectal cancer patients, only few of the tested 
factors were altered significantly compared to healthy volunteers. 
There was an imp01tant inter-patient variation leading to extensive 
overlap with the healthy subjects. If the Ievel of a given factor was 
directly related to the presence of the tumor, one would expect 
altered levels for it in a majority of the patients. This simple expect-
ation was not confirmed. SCF, PIGF and sVEGFR-1 were not 
increased in patients with tumors, whereas VEGF-A, sVEGFR-2, 
sTie-2, saVf33, EDB+ -Fn and MMP-9 showed some significant dif-
ferences compared to healthy donors, but with an important hetero-
geneity within patients. In breast and colorectal cancer patients, 
VEGF-A and MMP-9 were the 2 markers that best fulfilled the 
characteristics expected for surrogate marker of angiogenesis: they 
were elevated in patients before treatment (although only in about a 
third of the breast cancers and a half of the colorectal cancers), and 
their values dropped after tumor removal. Fourteen colorectal can-
cer patients and one breast cancer patient responded to tumor 
removal by a clear increase in sVEGFR-1 Ievels (Fig. 2b). The rea-
son for this change is not clear. VEGFR-1 is produced in 2 isoforms 
with contrasting fonctions in angiogenesis. The full-length trans-
membrane form stimulates angiogenesis by transactivating 
VEGFR-2, 14 promoting the release of hematopoietic and angio-
genic precursor cells from bone marrow, 15 stimulating the migra-
tion of monocjtes34 and activating Jung endothelial cells at preme-
tastatic sites.3 In contrast, the soluble form (sVEGFR-1), which 
consists of the extracellular domain as a result of alternative mRNA 
splicing, 16 binds and inactivates circulating VEGF-A36 and is con-
sidered to be an endogenous negative regulator of angiogenesis. In 
breast cancer, a low VEGFR-lNEGF-A ratio in the tumor tissue 
itself was rep01ted to be a poor prognostic factor. 37 One could 
hypothesize that in our patients, the tumor itself may inhibit 
sVEGFR-1 production, and that this inhibition is abrogated upon 
tumor removal. The implication of the increase in sVEGFR-1 
observed in some of the operated patients is unknown at this point. 
It should also be sh·essed that sVEGFR-1 can also be generated by 
proteolytic cleavage of the transmembrane fo1m at the cell surface. 
The assay used in our study does not allow to differentiate between 
the 2 forms. It is therefore possible that the sVEGFR-1 measured in 
these patients may consist of a mixture of the alternatively spliced 
variant, and of the proteolytically cleaved form. Because these 2 
forms may refiect different biological events or cellular sources, it 
may be worth to address this question in future studies. Compared 
to healthy volunteers, sVEGFR-2 and sTie-2 were slightly but sig-
nificantly increased (approximately 15-50 % of n01mal values). In 
contrast; the mean values of saVl33 and EDB+-Fn were several 
folds lower in cancer patients vs. healthy volunteers. The absence of 
correlation between the number of circulating platelets and the level 
of sa Vl33 suggests that platelets are unlikely to be the source of the 
saVl33 measured here. Although on a per platelet basis, aVl33 is 
much Jess abundant than aiibl33 (about 1,000 vs. 50,000 copies),38 
platelet-derived aVl33 could be of potential concern considering 
the large number of circulating platelets. The biological significance 
ofthese molecules as surrogate markers of angiogenesis is question-
able because their levels did not change after tumor removal. This 
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observation, however, raises the intriguing questions of whether 
these patients may have constitutively altered levels of these mole-
cules and whether altered levels may correlate with an enhanced 
angiogenic response or susceptibility to tumor progression ('predis-
position factors'). This hypothesis may be of particular relevance 
for cxVf33, because mice lacking cxVf33 expression were reported to 
have enhanced tumor angiogenesis and tumor growth.39 
CRP behaved as a tumor marker for colorectal cancer patients: 
it was significantly elevated before treatment and it returned 
within normal levels after surgery. The trend toward a positive 
association with VEGF-A and MMP-9 levels, although not as 
strong and between VEGF-A and MMP-9, hints at a possible asso-
ciation with angiogenesis. Apparently contrasting observations 
about a possible role of CRP in controlling angiogenesis exist in 
the literature. In multi~le myeloma CRP positively correlated with 
blood levels of VEGF 7•28 and with increased bone marrow angio-
genesis.40.41 Elevated levels of CRP were reported associated with 
a reduced number of circulating endothelial cell precursors in car-
diac patients,42 and CRP was shown to decrease survival, differen-
tiation and fonction of endothelial cell precursors43 and to inhibit 
angiogenesis by suppressing nitric oxide production.44 Although 
our results clearly associate elevated levels of CRP with the pres-
ence of colorectal cancer, more studies are necessary CRP levels 
can be linked to tumor angiogenesis. 
Among the 9 factors investigated we could only find a strong 
correlation between VEGF-A and MMP-9 levels, most notably in 
CRC patients (Fig. 3). To our knowledge, this correlation has not 
been described previously in the blood of patients with solid 
tumors, but it was seen in pleural effusions in patients with tuber-
culosis and lung cancer45 and in the plasma of patients with adult 
T cell leukemia.46 This correlation is consistent with preclinical 
data reporting functional interdependence between VEGF-A and 
MMP-9. VEGF-A can induce MMP-9 expression in different 
cells, whereas MMP-9 can promote the release of ECM- and cell 
surface-bound VEGF-A, thereby increasing its bioavailability. 
VEGF-A was reported to enhance production of MMP-9 by 
human vascular smooth muscle cells47 and to induce MMP-9 in 
pre-metastatic Jung endothelial cells and macrophages, thereby 
promoting lung metastasis formation. 35 In the Rip!Tag2 model of 
multistep carcinogenesis, increased MMP-9 activity promoted the 
release of matrix-bound VEGF-A resulting in the angiogenic 
switch and enhanced tumor progression. 19 In ovarian cancer cells 
MMP-9 activity ~romoted angiogenesis48 and dose-dependent 
VEGF-A release. 9 A correlation trend was found between 
increased levels of CRP and VEGF-A, and CRP and MMP-9 
(R2 = 0.43 and R2 = 0.36, respectively) and between IL-8 levels 
and VEGF-A and MMP-9 (R2 = 0.604 and R2 = 0.402, respectively). 
Although our study was not designed to demonstrate correla-
tions between the measured factors and clinical parameters, some 
interesting trends between VEGF-A or MMP-9 and clinical-patho-
logical characteristics, were nevertheless observed. In breast can-
cer, VEGF-A levels tended to be higher in patients with larger 
tumors, advanced tumor stages and more aggressive histology 
(higher grade, negative hormone receptor status). For MMP-9, a 
trend between elevated levels and larger tumor size and more 
advanced stages was also observed. In colorectal cancer patients, 
VEGF-A and MMP-9 values tended to be higher in patients with 
more advanced tumor stages, local infiltration and lymph node 
metastases. These observations are in line with published studies 
FIGURE 4 - (a) CRP values before treatment. Colorectal cancer 
patients had significantly higher levels compared to healthy volun-
teers. ILP patients also had increased levels but the difference was not 
significant (b) CRP values before and after treatment in colorectal can-
cer patients. (c) Values before and after treatment in ILP patients. HV, 
healthy volunteers; BC, breast cancer; CRC, colorectal cancer; ILP, 
sarcoma and melanoma patients. The short horizontal lines indicate 
mean values. 
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reporting correlations between circulating levels of VEGP-A and 
tumor stage,50'51 disease progression52•53 and patient survival54-56 
in different cancers. Elevated systemic levels of MMP-9 were 
reported to be associated to tumor infiltration, tumor stage, node 
metastasis and poorer survival57•58 in various cancers. 
In comparison to breast and colorectal cancer patients who were 
treated by curative surgical resection, we included 8 patients with 
advanced but still local tumors (i.e., limited to a limb) who 
received regional chemotherapeutic treatment by ILP. ILP allows 
local administration of high dose chemotherapy without affecting 
other organs leading to a high proportion of complete tumor 
regressions.59 The pattern of the measured factors before therapy 
in ILP patients was strikingly different compared to BC and CRC 
patients and is, in part related to the differences in the type, stage 
and size of the tumors. The systemic changes observed in ILP 
patients after therapy were nearly the opposite ofthose seen in sur-
gically treated patients: significant increase in VEGP-A, SCP, 
sVEGFR-2, MMP-9, sTie-2 and CRP, and decrease in sVEGFR-1 
levels. The rise in SCF level, although modest, may refiect an 
involvement of the bone marrow in mobilizing angiogenic endo-
thelial cell precursors or mast cells. 15 These changes are consistent 
with enhanced angiogenesis, whereas changes observed after sur-
gical tumor removal are consistent with decreased angiogenesis. 
TNP causes a selective and acute vascular damage to the tumor 
vasculature resulting in increased accumulation of melphalan in 
the tumor tissue, followed bJo a vascular collapse, and a massive, 
long lasting tumor necrosis: 0 TNP also elicits a systemic infiam-
matory response, as demonstrated by the increased systemic levels 
of sTNP-R2, IL-6, CRP and Tenascin-C.60•61 The increase in CRP 
concentration after ILP was confirmed here and its association 
with IL-8 levels suggests the possibility that a sustained infiamma-
tory reaction may persists in or around the treated tumors. Such a 
condition would be consistent with the reported upregulation of 
IL-8 in response to Ras activation, which is a paradigm of a sig-
naling pathway of tissue repair. 24 One can therefore postulate that 
sustained inflammation and tissue hypoxia may persist in and 
around necrotic tissues after ILP, thereby contributing to an 
'angiogenic switch' in these patients. If confirmed, this 'angiogenic 
switch' is likely to have potential clinical implications because it 
may favor re-growth of angiogenic vessels thereby promoting sur-
vival and growth of tumor cells not killed by the treatment. 
Among the patients analyzed, 5 experienced a loco-regional 
relapse and one developed distant metastases on both. It was, how-
ever, difficult to correlate progression with the degree of increase 
in the levels of these factors because of the small sample size. 
Two patients were treated by surgery after ILP (sarcoma) and 
tumor tissue was analyzed histologically. The patient with the 
highest degree of increase in VEGP and MMP-9 showed residual 
viable tumor tissue, whereas the patient who had only minor modi-
fications in the levels of VEGF, MMP-9 had complete histological 
remission. These 2 observations are consistent with the hypothesis 
that a putative angiogenic switch may occur in patients with 
incomplete anti-tumor response and residual tumor tissue persists 
after ILP. Because of the potential clinical relevance of this obser-
vation, we plan to prospectively compare VEGP-A, MMP-9 and 
sVEGP-Rl levels in patients with locally advanced sarcoma 
undergoing surgical tumor removal or ILP, respectively. In paral-
lel we Will evaluate the presence of hypoxie reSions in and around 
the tumors by position emission tomography. If this hypothesis 
is confirmed, the administration of an anti-angiogenic agent after 
ILP to suppress reactive angiogenesis may improve outcome. 
In conclu&ion, among ail factors measured, only VEGF-A and 
MMP-9 consistently c01Telated to each other, elevated CRP levels 
were associated with tumor burden, whereas sVEGP-Rl increased 
after tumor removal in colorectal cancer. Treatment with chemo-
therapy and TNP induced caused changes consistent with an 
'angiogenic switch.' These results warrant a prospective study to 
compare the effect of surgical tumor removal vs. chemotherapy on 
some of these markers and to evaluate their prognostic/predictive 
value. If the 'angiogenic switch' after ILP will be confirmed, we 
ANGIOGENESIS MARKERS IN PERIPHERAL BLOOD 763 
will consider the addition of an adjuvant anti-angiogenic therapy 
to counteract this potentially pro-angiogenic effect ofILP. 
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